Search results for "Piracetam"

showing 2 items of 12 documents

Efficacy of levetiracetam in the treatment of drug-resistant Rett Syndrome.

2010

Rett syndrome (RTT) is a progressive neurological disorder characterized by a wide spectrum of phenotypes. Epilepsy is reported to occur in 50–90% of patients with RTT; some develop medically refractory epilepsy. The aim of this study is to investigate the efficacy of levetiracetam (LEV) in drug-resistant patients with RTT. This prospective, pragmatic, open-label study consisted of an 8-week baseline period and a 6-month evaluation period. Efficacy variable was the mean frequency of monthly seizures before, and after 3 and 6 months of treatment with LEV. Eight female patients, aged 7.5–19 years (M12.8 ± 5) entered the study. Mean age at epilepsy onset was 25.8 ± 14.1 months. All patients sh…

Pediatricsmedicine.medical_specialtyLevetiracetamAdolescentMethyl-CpG-Binding Protein 2medicine.medical_treatmentRett syndromeNeurological disorderDrug Administration ScheduleCentral nervous system diseasedrug therapy/geneticsYoung AdultEpilepsyanalogs /&/ derivatives/therapeutic useSeizuresConvulsionmedicineRett SyndromeHumansgeneticsEEGProspective StudiesMyoclonic seizuresChildProspective cohort studyPsychiatryDrug-resistanceAnalysis of Variancebusiness.industryPatient SelectionFocal seizureElectroencephalographymedicine.diseaseAdolescent Analysis of Variance Anticonvulsants; therapeutic use Child Drug Administration Schedule Electroencephalography Female Humans Methyl-CpG-Binding Protein 2; genetics Patient Selection Piracetam; analogs /&/ derivatives/therapeutic use Prospective Studies Quality of Life Rett Syndrome; drug therapy/genetics Seizures; drug therapy/genetics Treatment Outcome Young AdultPiracetamSettore MED/39 - Neuropsichiatria InfantileTreatment OutcomeAnticonvulsantNeurologytherapeutic useQuality of LifeAnticonvulsantsFemaleNeurology (clinical)Levetiracetammedicine.symptombusinessmedicine.drug
researchProduct

Neue Antiepileptika in der Entwicklung. Substanzen mit neuen Wirkmechanismen

2007

Unbestritten ist, dass sich durch den Einsatz von Antiepileptika der 2. Generation die Situation fur Epilepsiepatienten entscheidend verbessert hat. Dennoch bleibt ein Patientenklientel, bei dem keine ausreichende Anfallskontrolle erreicht wird, das therapierefraktar ist oder im Verlauf der Behandlung wird. Weiterentwicklungen von AEDs aus der 2. Generation (“follow-up compounds”) bzw. Wirkstoffe mit neuen Strukturen und Wirkmechanismen konnten zukunftig diese Lucke fullen.

PharmacologyValproic Acidbusiness.industrymedicinePharmaceutical SciencePiracetamPharmacology (medical)CarbamazepineLevetiracetamPharmacologybusinessmedicine.drugFelbamatePharmazie in unserer Zeit
researchProduct